SCHEMBL7815243

SCHEMBL7815243

Cn1[c]nc2cccc(Cl)c21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.47
PSMB8 P28062 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.33
HSD11B1 P28845 1/20 0.32
PARP1 P09874 1/20 0.31
ADRA2A P08913 1/20 0.31
CYP2D6 P10635 1/20 0.31
ADRA2B P18089 1/20 0.31
ADRA2C P18825 1/20 0.31
ADRA1D P25100 1/20 0.31
ADRA1A P35348 1/20 0.31
ADRA1B P35368 1/20 0.31
ESR1 P03372 1/20 0.31
TP53 P04637 1/20 0.30
PRPS1 P60891 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2A6 P11509 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
DRD2 P14416 1/20 0.30
DRD3 P35462 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7804906 0.78 NPC1 (0.41) SMN1; SMN2PARP1ESR1CYP1A2CYP2A6
SCHEMBL8566833 0.78 PRMT5 (0.41) PRMT5PSMB8PARP1CYP1A2CYP2A6
SCHEMBL5840891 0.77 BACE1 (0.32) PRPS1
SCHEMBL7812481 0.77 SIRT2 (0.33) PRPS1
SCHEMBL17186937 0.77 PRMT5 (0.40) PRMT5PSMB8SMN1; SMN2ESR1
SCHEMBL5000469 0.74 PRMT5 (0.41) PRMT5PSMB8PRPS1
SCHEMBL3656354 0.72 DHODH (0.35) TP53NPSR1
SCHEMBL5006517 0.71 GRM2 (0.36) PRMT5PSMB8SMN1; SMN2HSD11B1PARP1
SCHEMBL4555147 0.70 CRHR1 (0.30)
SCHEMBL7805418 0.67 GABRA2 (0.36) PRPS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0745600-B1 Benzimidazole derivatives, their preparation and their therapeutic use SANKYO CO (JP) 2001-10-24 EP disclosed
US-5886014-A TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS SANKYO COMPANY, LIMITED (JP) 1999-03-23 US disclosed
EP-0745600-A1 Benzimidazole derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-12-04 EP disclosed